COLORADO SPRINGS, Colo.–(EON: Enhanced Online News)–Cannabis Science, Inc. (OTCBB:CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to announce its FDA progress resulting from the last meeting with the Company’s FDA Specialist team to officially determine that the target indication will be for a topical application for skin cancer.
Cannabis Science has already seen first hand success in reducing the tumor burden in basil and squamous cell carcinoma, two forms of skin cancer. The company website http://cannabisscience.com photo-documents tumor shrinkage and disappearance after the self-administration of topical cannabis extract treatment by four skin cancer patients. As a consequence of these anecdotal observations, Cannabis Science is confident of the need and opportunity to enter the prescription drug market. Our advisors are preparing the required submission for a pre-IND application to the FDA for our topical skin cream/extract for skin cancer.
Cannabis Science is excited to pursue these investigations with the help of our FDA specialists. Cannabis Science is overseeing additional successes with other self-medicating cancer patients suffering from a variety of other cancers. Reports of their progress will be made available as treatments progress and are confirmed.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.